GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (HAM:407) » Definitions » FFO

Sensei Biotherapeutics (HAM:407) FFO


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics FFO?

FFO (Funds from operations) only applies to REITs.


Sensei Biotherapeutics (HAM:407) Business Description

Traded in Other Exchanges
Address
1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.